Modeling the Pharmacoeconomic Cost of Three Selective Serotonin Reuptake Inhibitors

Antidepressant medications were prescribed for 77 percent of the 2,779 patients, or 2,140 patients. Eighty-one percent of the patients who received an antidepressant—a total of 1,733 patients—received an SSRI; 9 percent, or 193 patients received a novel antidepressant; and 10 percent, or 214 patients, received a tricyclic antidepressant. Of the patients who were prescribed SSRIs, 28 percent, or 485 patients, received fluoxetine; 18 percent, or 317 patients, received paroxetine; and 54 percent, or 931 patients, received sertraline. Mean doses with 95 percent confidence intervals were 26 mg (CI=23 to 33 mg) for fluoxetine, 24 mg (CI=21 to 26 mg) for paroxetine, and 84 mg (CI=76 to 92 mg) for sertraline. Seventy percent of the patients who received fluoxetine and 80 percent of the patients who received paroxetine completed treatment with a final dose of 20 mg or less. Among patients who received sertraline, 84 percent had a final dose of 100 mg or less, and 51 percent had a final dose of 50 mg or less.

Table 1 shows the actual average drug cost per day for each of the three SSRIs determined by calculating the costs for the percentage of patients on each daily dose (sum of distribution times cost divided by day). The average costs per day using this method are $1.79 for fluoxetine, $1.41 for paroxetine, and $1.21 for sertraline.

These results contrast with those that would be obtained from the common but incorrect approach using cost per milligram of the average dose (cost times average dose divided by tablet size). That method would report average costs per day of $1.68 for fluoxetine using 20 mg tablets, $1.58 for paroxetine using 20 mg tablets, $1.17 for sertraline using 100 mg tablets, and $2.32 for sertraline using 50 mg tablets.

Several limitations of the generalizability of these results should be mentioned. The naturalistic method for assessing medication effectiveness does not substitute for a randomized controlled efficacy study in which patients are systematically assessed and assigned to study groups in terms of diagnosis, outcome measures, SSRI used, and dose titration. There was no difference in the outcome variables, with the exception that patients who switched medication were in treatment 40 percent longer than those who did not switch.

Levels of sertraline use may have been higher to the extent that patients were referred or returned to the primary care setting in which sertraline is the primary SSRI in the institutional formulary. An ascertainment bias affecting dosages must be considered because this clinic is an academic tertiary care center serving a population with lower socioeconomic status and with potentially greater illness severity and comorbidity. Given these parameters, the SSRI dosage means and use of halved 100 mg tablets of sertraline are consistent with reports from other settings (6,7). If 50 mg tablets of sertraline were used instead of halved 100 mg tablets, the average cost of sertraline would be $.35 higher.

Costs and dosage distributions reported here were used only to demonstrate a correct pharmacoeconomic cost-minimization analysis. Other settings should use their own medication acquisition costs and dose distributions to determine comparisons. We emphasize that no particular SSRI is being promoted.

The stratification methodology correctly determines average drug cost per day by calculating the percentage of patients on each daily dose. In the study setting described here, this analysis demonstrated that using halved 100 mg tablets of sertraline for 50 mg doses is less expensive ($1.21 per day) than using paroxetine ($1.41) or fluoxetine ($1.79). The average sertraline cost is determined correctly—costs for both 50 mg and 100 mg tablets are taken into account rather than considering different costs for each size of tablets in determining the cost per mg relative to average dose in the sample. Drug costs based on the cost per milligram of average doses are misleading because they fail to account for different pill costs as applied to patient dose distribution. In the sample reported here, this method would overestimate the actual costs of using 50 mg tablets of paroxetine and sertraline and underestimate the cost of using 100 mg of fluoxetine and sertraline.

Due to competitive market forces, practitioners and others who are responsible for drug acquisition are confronted with an array of claims of effectiveness when selecting an SSRI for patients. In the economic arena, those who attempt to illustrate the highly contentious issue of a medication's cost-efficiency frequently embrace unproven methodologies or use methods that cost out direct expenses, such as those for drugs, clinical visits, and laboratory tests, along with indirect expenses such as loss of life, earnings, and productivity. Often what appear to be unbiased analyses serve a less apparent agenda. Due to the complexity of such methods, they are difficult to assess critically.

We suggest that until superior clinical efficacy and effectiveness can be demonstrated conclusively for a particular SSRI or other antidepressant, acquisition costs, if analyzed correctly, can help guide the choice of agent for a population when indicators for use of a specific agent are absent.

The authors thank Michael P. Dutro, Pharm.D., for technical assistance and advice during the study.

The authors are affiliated with the department of psychiatry at the School of Medicine of the University of New Mexico Health Sciences Center, 2600 Marble Avenue, N.E., Albuquerque, New Mexico 87131 (e-mail, [email protected]).